Systolic Hypertension in the Elderly Program, Pilot Study (SHEP-PS): morbidity and mortality experience.
SHEP-Pilot Study, a randomized, double-blind, placebo-controlled trial of drug therapy for isolated systolic hypertension, followed 551 participants aged 60 years or more with untreated blood pressures of greater than or equal to 160/less than 90 mmHg for an average of 34 months. Mean age was 72 years, 63% were female and 82% white. Pretreatment blood pressures averaged 172/75 mmHg. As their Step I drug, 443 participants were assigned chlorthalidone and 108 placebo. Of 512 surviving participants, 80% and 84% of the chlorthalidone and placebo groups, respectively, attended their last clinic visit; 71% and 60% were still taking blinded drug; and 60% and 33% had systolic blood pressures less than 160 mmHg. Final blood pressures averaged 140/67 and 154/72 mmHg for the chlorthalidone and placebo groups, respectively. All-cause mortality rates were 25 and 23 deaths per 1000 participant-years of risk, respectively; rates for 'definite' first strokes were 8.3 and 13 deaths. Differences between chlorthalidone and placebo groups were significant for blood pressure but not for event rates.
Perry
H M
HM
McDonald
R H
RH
Hulley
S B
SB
Smith
W M
WM
Furberg
C D
CD
Greenlick
M R
MR
Kuller
L H
LH
Schnaper
H W
HW
Schoenberger
J A
JA
Vogt
T M
TM
D000368:Aged; D000375:Aging / Q000502:physiology*; D002752:Chlorthalidone / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D010865:Pilot Projects; D014481:United States
D002752:Chlorthalidone